Takeda submits vedolizumab BLA

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) submitted a BLA to FDA for vedolizumab to treat moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD). The pharma submitted an MAA ...